AGORA PHARMACEUTICALS, S.R.O.

COMPANY INTRODUCTION •  established in 2015

•  biotech company focused on the development of novel drugs against neurodegenerative diseases, in particular, Alzheimer´s disease

•  company management is made up of world-renowed researchers in Alzheimer´s disease field

o  prof. MUDr. Jakub Hort, Ph.D. – neurologist; Head of the Centre for Cognitive Disorders (University Hospital Motol)

o  doc. MUDr. Martin Vališ, Ph.D. – neurologist; Head of the Neurological Clinic (University Hospital Hradec Králové)

o  prof . Ing. Kami l Kuča, Ph.D. – chemist & tox ico log is t ; researcher (University of Hradec Králové)

o  Dr. Manfred Windisch, Ph.D. – pharmacologist engaged in the development of animal models of Alzheimer´s disease

ALZHEIMER´S DISEASE

•  neurodegenerative disease

•  development of effective therapeutics against Alzheimer´s disease is one of the major challenges of the 21st century

•  due to ever-increasing life expectancy it is estimated that the number of patients suffering from this disease will double by 2050

•  current treatment is only symptomatic and provides a relief for up to 3 years; it does not cure the cause of the disease

OUR VISION

•  combination therapy – affects several pathological mechanisms simultaneously → increases the overall therapeutic effect

•  combination of symptomatic drugs and the drugs that stop one of the causes of the disease → symptomatic relief and blockade of disease progression

•  investigation on novel targets for treatment of Alzheimer´s disease

MARKET POWER

•  in 2018/2019 huge pharmaceutical companies asPfizer or Roche cancelled scientific groups dealingwithAlzheimer´sdiseaseforlackofpositiveresults

Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimers Dement (N Y). 2019; 5:272-293.

OUR SOLUTION

•  Three different projects by now (Agora 1, Agora 2, Agora 3)

•  Each of them different approach how to combat Alzheimer´s disease

•  Each of them in different development stage

•  Different Alzheimer´s disease pathways as targets for our drug candidates to minimize the failure

More information on request